Since the 2016 Brexit vote, there has been considerable uncertainty around the future of drug and medtech regulation in the UK. This article explores the potential routes towards a mutual recognition agreement and how this could be achieved through representation by the life sciences industry.

The NHS Commercial Framework for New Medicines has been published. It aims to support patient access to affordable and transformative medicines. MAP provides insights into the effect it will have on the industry going forward.

The New NHS White Paper on reforming the NHS, Integration and Innovation: working together to improve health and social care for all, which was foreshadowed in MAP’s blog on 9 February, was published on 11 February.